Etanercept Articles
Mylan delivers "one pill once a day" ARV in South Africa; Cipla Debuts first Enbrel biosimilar
17 April 2013
FDA accepts file for new Actemra formulation in rheumatoid arthritis
28 February 2013
Steady sales for MAbs in rheumatoid arthritis - can biologics beat the patent cliff?
13 February 2013
Global rheumatology market controlled by Enbrel, Humira and Remicade
24 December 2012
Amgen’s gets new US patent for Enbrel, giving protection until 2028
24 November 2011
Study identifies factors linked with better medication response for treatment of juvenile arthritis
7 November 2011
Remicade, Humira and Enbrel made up 40% of the immunomodulators market in 2010; report
23 August 2011
Europe’s CHMP adopts positive opinions on Dexdor, Incivo, Plenadren, Vyndaqel and Zytiga; backs extensions
23 July 2011
New data offer insights into TNF non-responders actively switched to Johnson & Johnson’s Remicade
9 November 2010
New Zealand’s PHARMAC seals deal with Pfizer for new kidney cancer, smoking cessation and arthritis drugs
1 November 2010
Psoriasis drug market expected to double to $6.8 Billion in 2019, driven by biologics penetration and Interleukin/TNF-alpha inhibitors
10 August 2010
Increasing competition from other biologics will continue to erode Enbrel's dominance in the psoriasis drug market, DR report concludes
12 February 2010
UK’s NICE says “no” to Novartis’ Afinitor for advanced RCC and delays Sprycel and Tasigna; Scotland backs Alimta and Stelara
9 February 2010
Burst of M&A activity in pharma during 2009 led by mega-deals from Pfizer/Wyeth and Merck & Co/S-P
4 February 2010
Amgen's fourth quarter 2009 earnings slightly below consensus analyst’s expectations
26 January 2010
UK’s NICE does about turn on UCB’s Cimzia, backing it use for RA, but with cost-sharing deal
21 January 2010
FDA finally approves Roche’s Actemra for moderately-to-severely active rheumatoid arthritis
11 January 2010
Biosimilars of TNF-alpha inhibitors stand to erode over $9 billion in brand sales in USA and Europe by 2018
4 November 2009
Cost-cutting helps Amgen lift 3rd quarter 2009 EPS 21%
22 October 2009
UCB’s Cimzia approved for RA in Europe
7 October 2009
$4 million milestone for Ablynx in Nanobody deal with Wyeth
1 October 2009
Janssen-Cilag's Stelara backed by UK’s NICE for moderate-to-severe plaque psoriasis
23 September 2009
Health Canada working to update labeling of TNF blockers
29 August 2009
US FDA says cancer warnings required for TNF blockers
5 August 2009
Retail drug sales in year to March 2009
22 May 2009
Wyeth's first-quarter 2009 profit flat year-on-year as it prepares for Pfizer mega-merger
29 April 2009
Falling profit on low sales for Amgen
27 April 2009
Retail drug sales in year to February 2009
24 April 2009
Retail drug sales in year to January 2009
3 April 2009
Japan stock market week to March 23, 2009
30 March 2009
Retail drug sales in year to December 2008
30 March 2009
Retail drug sales in year to November 2008
26 January 2009
Wyeth in talks to acquire Crucell; sources say potential offer could be up to $1.35B
12 January 2009
Retail drug sales in year to October 2008
22 December 2008
Wyeth presents new Enbrel PA data
15 December 2008
Good news for Wyeth from CHMP
1 December 2008
Lasting benefits of CEL-SCI's RA vaccine demonstrated
24 November 2008
Retail drug sales in year to September 2008
17 November 2008
Wyeth presents on two Ph IV AS trials of Enbrel
3 November 2008
Wyeth's 3rd-qtr profit flat; AD drug delayed
3 November 2008
Amgen's 3rd-qtr 2008 profit leaps to $1.16B
3 November 2008
Retail drug sales in year to August 2008
20 October 2008
Ariad gets favorable court ruling on Amgen litigation
13 October 2008
SPD Minister attacks Germany's drugmakers
29 September 2008
Wyeth's Enbrel could help QoL in psoriasis
29 September 2008
Retail drug sales in year to July 2008
22 September 2008
US FDA calls for tougher warnings on TNF-alpha drugs on 240 cases of histoplasmosis
15 September 2008
Retail drug sales in year to June 2008
18 August 2008
Amgen earnings down but outlook still up
4 August 2008
Retail drug sales in year to May 2008
4 August 2008
Retail drug sales in year to April 2008
28 July 2008
NICE rejects second-line use of TNF-alpha drugs
28 July 2008
EC clears higher dose of Wyeth
14 July 2008
Japan stock market week to July 7, 2008
14 July 2008
CORRECTION: Enbrel recommendation
30 June 2008
Amgen/Wyeth receive OK from FDA for Enbrel
30 June 2008
Wyeth reports positive data from COMET trial
30 June 2008
Enbrel improves two measures of remission
23 June 2008
Retail drug sales in year to March 2008
16 June 2008
Retail drug sales in year to February 2008
19 May 2008
Amgen reports nearly flat 1st qtr
5 May 2008
Wyeth beats forecasts despite generics
5 May 2008
"Condemned to a life of misery" by UK's NICE
5 May 2008
Retail drug sales in year to January 2008
21 April 2008
Boxed warnings for Amgen/Wyeth's Enbrel
24 March 2008
Centocor's psoriasis drug accepted for FDA review
10 March 2008
Ustekinumab: "gold standard" for psoriasis by 2011
18 February 2008
Wyeth's 4th-qtr 2007 income climbs 18% just shy of estimates; predicts flat 2008 on generic competition
11 February 2008
Encouraging early AD data with anti-TNF drug
21 January 2008
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
